- Animal Model
- Cardiovascular - Cardiology
- Endocrine - Metabolic
- Gastroenterology - Hepatology
- Gene Therapy
- Immunology - Allergy
- Infection - Infectious Diseases
- Obstetrics & Gynecology
- Oncology - Cancer
- Orthopedics - Musculoskeletal
- Orthopedics - Muskuloskeletal
- Psychiatry - Psychology
- Small Molecule
- Urology - Nephrology
- Vascular - Pulmonary
New technologies delivered to your inbox Subscribe
Matrix Metalloproteinase Inhibition to Slow Calcification and Failure of Bioprosthetic Aortic Valves
2010-060 – Calcific aortic valve stenosis is a growing problem in developed countries, and valve replacement surgery is the second most common thoracic surgery performed worldwide (>100,000 procedures performed in the US in 2008). Bioprosthetic valves are the most commonly used devices to replace the stenotic valve, but only have a projected lifespan of 10-12 years. During this time, endothelial... Read More
2009-374 – Technology Description An immunotherapy approach that delivers multiple antigens within a vesicular stomatitis virus (VSV) vector. The delivery of multiple antigens allows for a multipronged immune response against a tumor while the VSV vector serves as an activator of the innate and adaptive immune response. A three antigen combination delivered via a VSV vector has been demonstrated to be... Read More
2009-173 – Insulin-Stimulating Peptides for Diabetes and Metabolic Disorders Mayo Clinic Researchers have developed a series of peptides that have been shown to modulate glucose levels and reduce fibrotic damage to the heart and kidneys in diabetic animal models. These peptides are structural analogs of glucagon-like peptide (GLP) and natriuretic peptides. Application Control of glucose levels in... Read More
2009-172 – Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene and is currently used for the management of DM. We have created a peptide with GLP-1 Properties.
2009-139 – Technology Description Mayo Clinic researchers have exploited normal blood-brain barrier (BBB) transport mechanisms utilized by apolipoproteins to deliver agents across the BBB and have designed peptides incorporating apolipoprotein LDL receptor binding sequences. These peptides contain additional amino acid sequences to facilitate the binding and delivery of various biological and chemical... Read More
2009-131 – CD2 Binding Agents for Decreasing Suppressive Monocytes in Cancer and Sepsis CD2 binding molecules, such as alefacept, have been shown to deplete immunosuppressive monocytes (e.g., CD14+/DR- or CD14+/DRlow) in patients with lymphoma. Increased levels of immunosuppressive monocytes have been found to be associated with poor prognosis. Continued depletion of immunosuppressive monocytes appeared... Read More
2008-325 – The invention described herein is a method by which to visually verify and quantify the amount of radiation dose delivered to a patient during the administration of radiation therapy. A Compton camera imaging system is used to detect and reconstruct the original interaction position and energy of photons that are scattered out of the patient during treatment. The result is a three... Read More
2008-332 – Both natural and chimeric natriuretic peptides have anti-proliferative properties i.e. they prevent abnormal growth, in muscle cells, endothelial cells and fibroblast cells. Blocked arteries and veins are a common cause of cardiovascular problems and blockage of muscular tubes, such as the ureter or esophagus can result serious complications. Stents are currently used to unblock blood vessel... Read More
2008-322 – Synthetic atrial natriuretic peptide (ANP) (carperitide) and B-type natriuretic peptide (BNP) (nesiritide) are used to treat congestive heart failure. However, despite beneficial cardiac unloading properties, reductions in renal perfusion pressures limit their clinical effectiveness. Recently, CD-NP, a chimeric peptide composed of CNP fused to the carboxyl terminal tail of Dendroaspis... Read More
Aquaporin-4-Binding Autoantibodies in Patients with Neuromyelitis Optica Impair Glutamate Transport by Down-Regulating EAAT2
2008-303 – Materials and Methods for Treating Neuromyelitis Optics (NMO) Methods for treating NMO are claimed including the use of glulamate receptor antagonists and/or compounds that inhibit complement.
2008-266 – In multiple animal models of cardiovascular disease, including hypertrophic cardiomyopathy (enlargement of the heart), dilated cardiomyopathy (dilation and weakening of the heart), and heart failure (ineffective heart function), a protein which plays a key role in the heart is lost - junctophilin type-2 encoded by the gene JPH2. Our invention, a “recombinant junctophilin - 2”, provides a... Read More
A Novel Series of Designer Peptides Combining Angiotensin - (1-7) With Selected Amino Acid Sequences from the Natriuretic Peptides and a Novel Strategy of Co-Administration of Angiotensin - (1-7) With a Native or Designer Natriuretic Peptide
2008-179 – Our research focuses on the discovery and development of new drugs for the prevention and treatment of diseases affecting the heart, the blood vessels, and the kidneys. We have designed a novel series of ten peptides by combining angiotensin-(1-7) with selected amino sequences from the natriuretic peptides, as both angiotensin-(1-7) and the natriuretic peptides have been demonstrated to exert... Read More
2008-144 – Antibiotics fail when pathogens acquire genes that confer resistance to these drugs. This invention proposes generating vaccines specifically against the gene products of antibiotic resistance genes. These vaccines have the potential to counterselect against drug-resistant pathogens or may be used as an adjuvent to enhance drug therapy with the antibiotic by depleting the resistance gene. The... Read More
2008-001 – Adenoviruses are used for gene therapy, vaccines, and cancer killing. For gene therapy and vaccine they are generally used as non- “live” viruses and cannot make more of themselves. For cancer killing they are “live” and kill cells. This invention utilizes “single-cycle” adenoviruses for vaccine and other applications where the virus is engineered to only undergo one round of its life cycle... Read More
2007-328 – Cardiovascular disease is the leading cause of death in the United States. Our research focuses on the discovery and development of novel therapies for protecting the heart and the kidneys against harmful effects of ischemia (inadequate blood supply), heart failure, and high blood pressure. We have designed a novel peptide by combining amino acid (AA) sequences from the human natriuretic... Read More
2007-293 – Cardiovascular disease is the leading cause of death in the United States. Our research focuses on the development of novel therapies for protecting the heart and the kidneys during vulnerable periods of inadequate blood supply (ischemia) and upon restoration of blood flow (reperfusion). We designed a series of peptides by combining amino acid (AA) sequences from human natriuretic peptides... Read More
A Novel Series of Designer Natriuretic Peptides Combining the Natriuretic Peptides and Angiotensin-(1-7)
2007-196 – Heart Failure (HF) is an important public health problem and is the leading cause of hospitalization in adults over 65 years of age. Our research focuses on the development of novel therapies for the treatment of heart failure and other cardiorenal disease states. The first of this series of designer peptides is CLJB1c which consists of human C-type natriuretic peptide and angiotensin-(1-7),... Read More
2006-244 – Your Path to Smokeless Tobacco Freedom (Your Path) MC6013-01, is a new intervention booklet for patients who use smokeless tobacco that has been designed by the Nicotine Dependence Center (NDC) counselors and physicians with an emphasis on a patient-centered therapeutic approach to tobacco treatment. Your Path uses the spirit and tools of motivational interviewing to facilitate behavior... Read More
Mayo Clinic Nicotine Dependence Education Program: Customized Workshops for Health-Care Professionals
2006-243 – A training program to teach health-care professionals how to effectively treat patients who use tobacco. The staff of the Mayo Clinic Nicotine Dependence Center (NDC) works with the workshop organizer to develop a curriculum that fits the needs of the participants. Workshops can range in duration from ½ day to 5 days, depending on the depth of knowledge and skills requested. Faculty is... Read More
2006-224 – This is to provide knowledge about the use of neurotensin receptor agonists for treatment of various medical problems, including acute and chronic pain due to various causes and abuse of various types of psychostimulants (such as nicotine, cocaine, and amphetamines).
2006-159 – The natriuretic peptide family consists of natural hormones involved in the maintenance of fluid and sodium levels through their interactions with the heart and kidneys. Mayo Clinic researchers have developed a novel natriuretic peptide (ABC) which is made up of a unique amino acid sequence designed to preferentially target the kidney to preserve its function and protect it from... Read More
2006-154 – To increase progranulin in animals, progranulin levels and biologically active fragments of progranulin can be elevated in animals by direct administration of the protein or its fragments, either in the presence or absence of agents that stabilize the biological activity. Routes of delivery include, but are not limited to, intranasal, oral, inhalation, intracerebro-ventricular injection,... Read More
2005-237 – A protein from the fungus alternaria which induces recruitment and activation of eosinophils.
2005-172 – Serotype selective and nonpeptidic inhibitors of botulinum neurotoxin serotype A (BoNTA) have been developed. These inhibitors are effective in detoxifying botulinum neurotoxin serotype A; they can be used as therapeutics for treating food poisoning by BoNTA, overdose of BoNTA-based cosmetics such as Botox, and they can also be used as countermeausres to BoNTA-based biological weapons.
2005-165 – The use of HIV protease inhibitors in HIV negative patients increases naive T cell production, which may be useful in helping to boost immune responses. Potential uses include enhancing responses to immunizations, boosting immune function in patients with cancer, and/or immune deficiency disorders.
2005-131 – A guide for the use of the patient intervention manual: “My Path to a Smoke Free Future”. It contains rationale for each section of the manual, highlights of key points to be covered during the consultation and examples of phrases to use to explain the key concepts to patients. It is designed for the health care professional to maximize the use of the intervention manual. The accompanying DVD... Read More
My Path to a Smoke-Free Future - An Interactive Patient Manual (Suite of Products Including Certification)
2005-112 – An interactive patient manual to assist the health care provider in delivering an effective intervention to patients who use tobacco. The structure of the manual with graphs and illustrations is supported by a motivational approach and is designed to facilitate behavior change when used by a trained health care provider as part of the intervention. It is not another self-help material, but... Read More
2004-268 – Technology Description Mayo Clinic researchers have demonstrated that cAMP inhibitors, such as somatostatin analogs, are effective in treating polycystic liver disease in both animal models and in clinical studies. Current therapeutic options for polycystic liver disease primarily involve surgery, including liver cyst fenestration, and liver resection or liver transplantation. The... Read More
Discovery and Identification of Naturally Processed and Presented HLA Class II Measles Vaccine Virus Peptides
2004-011 – Two measles vaccine virus-derived peptides, from the nucleoprotein (N peptide) and Phosphoprotein P peptide). Specifically, 1) N-1 peptide: SAGKVSSTLASELG (14 amino acid peptide); 2) P-1 peptide: ASDVETAEGGEIHELLRLQ (19 amino acid peptide)
2003-149 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2003-048 – Method to Optimize Antigen Expression When Culturing Cells for Cancer Vaccines The culture of cells for use in cancer vaccines or for use in the discovery of tumor antigens occurs in a standard oxygen pressure environment of about 20 kilopascals (kPa). Mayo Clinic researchers have discovered that culturing cancer cells in a low (2 kPa) or high (90kPa) oxygen pressure increases expression... Read More
Synthesis of Poly (caprolactone-fumarate) Polymer as a Novel Biocompatible, Bioresorbable, Injectable, and In-situ Hardening Scaffold for Tissue Engineering Applications
2003-044 – Mayo Clinic researchers have created a biocompatible and bioresorbable PCF material for injectable and in-situ scaffolds by polymerizing a PCF macromer with a salt of fumaric acid that self-crosslinks.
2002-244 – Mayo has discovered a gene, PKHDL1, that shows significant homology to PKHD1 (the gene mutated in autosomal recessive polycystic kidney disease that was discovered at Mayo and for which a patent application is pending). The protein predicted to be encoded by PKHDL1, fibrocystin-L, is a large receptor-like protein that is highly expressed on T lymphocytes. The protein is postulated to be an... Read More
2002-226 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the increase and/or maintenance of bone density, osteoporosis, Paget’s disease, or any disease or condition in which bone loss is a factor.
Modulation of Toll-like Receptor 4 Signaling, or Other TLRs for Treatment or Prevention of Obesity and Excess Fat
2002-225 – Our invention is the use biological, pharmacological or saccharide intervention, genetic modification or selection, for antagonist or modulation of Toll-like receptor 4 (TLR4) or other TLRs for the maintenance, or reduction of fat body mass, obesity or any related conditions or diseases where body fat is a contributing factor.
2002-068 – Mayo Clinic researchers have created microspheres between 1-300 micrometers comprising a blend of cross-linkable PPF for the immobilized controlled release of any bioactive agent.
2001-153 – Circulating smooth muscle progenitor cells (SPC) in humans.
2001-152 – Technology portfolio related to Pharmaceutical Dosage Form for Colonic Delivery, Pharmaceutical Dosage Form With Multiple Enteric Polymer Coatings for Colonic Delivery, and Bisacodyl Dosage Form with Multiple Enteric Polymer Coatings for Colonic Delivery
2001-127 – Technology Description Compositions and methods have been developed for detecting plaques and treating CNS disorders. Polyamine modification of amyloid beta peptides or antibodies binding to amyloid beta increases blood-brain barrier (BBB) permeability and incorporation of a contrast agent permits MRI detection of plaque deposits. A novel peptide-based imaging agent has also been developed... Read More
2000-080 – The treatment of neutrophil-associated pulmonary inflammation including chronic obstructive pulmonary disease (smoker’s bronchitis), chronic bronchitis, cystic fibrosis, alphal-antitrypsin deficiency, adult respiratory distress syndrome and idiopathic pulmonary fibrosis by lidocaine inhalation.
1999-061 – This is a cell therapy delivery system which allows efficient and long term vascular delivery.
1998-076 – Short term paralysis of underlying musculature to improve cutaneous wound healing in tramatic and non-tramatic wounds.
1998-066 – The Mayo Clinic is developing and testing a synbiotic (composition of synergistic probiotic organisms and a prebiotic) for clinical indications (Croh'n’s, IBD, immunocompromised patients, patients undrgoing chemo or radiation therapy, patients infected with antibiotic resistant organisms. THe synbiotic has proven to be very effective in several animal trials including animals that were... Read More
1998-009 – Multiple myeloma is a universally fatal plasmaproliferative disorder despite aggressive chemotherapy and transplantation. An immunotherapeutic approach to target myeloma cells for killing by toxin genes or radioisotopes may be very useful therapeutically in myeloma and such approaches have already been shown to have clinical activity in other malignancies. Our investigators have devised a... Read More
1997-014 – A novel, topical chemotherapeutic drug in vanishing cream to treat malignancy.
1997-001 – With the aging of the population, osteoporosis is emerging as a major public health problem. Drugs used to treat osteoporosis can be classified into those that decrease bone resorption and those that increase bone formation. While a number of anti-resorptive therapies for osteoporosis are presently available, there is a clear need for novel anabolic approaches. New insights gained from a... Read More
1996-106 – Mayo has issued patent claims for inhibiting hydroxymethylglutaryl coA reductase activity to slow heart valve degeneration.